(Q37157631)

18 August 2017

1 reference

title

New-generation antidepressants, suicide and depressed adolescents: how should clinicians respond to changing evidence? (English)

1 reference

18 August 2017

0 references

1 reference

Tania Perich

4

0 references

Dusan Hadzi-Pavlovic

series ordinal

2

object named as

Dusan Hadzi-Pavlovic

1 reference

18 August 2017

Michael Dudley

1

1 reference

18 August 2017

Doug Andrews

series ordinal

3

1 reference

18 August 2017

publication date

1 June 2008

1 reference

Australian and New Zealand Journal of Psychiatry

18 August 2017

published in

1 reference

18 August 2017

volume

42

1 reference

18 August 2017

issue

6

1 reference

18 August 2017

page(s)

456-466

1 reference

Suicidality in pediatric patients treated with antidepressant drugs

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: a controlled forensic database study of 14,857 suicides

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Antidepressants and the risk of suicidal behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Utah youth suicide study: psychological autopsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Do antidepressants precipitate youth suicide?: a nationwide pharmacoepidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

The relationship between antidepressant prescription rates and rate of early adolescent suicide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Anti-depressants, suicide, and drug regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

The antidepressant quandary--considering suicide risk when treating adolescent depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Depression, antidepressants and suicidality: a critical appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Efficacy and safety of antidepressants for children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Suicidal adverse events in pediatric randomized, controlled clinical trials of antidepressant drugs are associated with active drug treatment: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Do antidepressants cause suicidality in children? A Bayesian meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

The flawed basis for FDA post-marketing safety decisions: the example of anti-depressants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

ACNP Task Force report on SSRIs and suicidal behavior in youth

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Review of the efficacy and safety of antidepressants in youth depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Antidepressants in child and adolescent depression: where are the bugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Should the use of selective serotonin reuptake inhibitors in child and adolescent depression be banned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Differences in early childhood risk factors for juvenile-onset and adult-onset depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

The mental health of young people in Australia: key findings from the child and adolescent component of the national survey of mental health and well-being

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Risk factors for suicide and attempted suicide among young people

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

National estimates of antidepressant medication use among U.S. children, 1997-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Relative mortality from overdose of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Are child-, adolescent-, and adult-onset depression one and the same disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Tricyclic drugs for depression in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Efficacy of antidepressants in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Rethinking childhood depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Perspectives on the efficacy of antidepressants for child and adolescent depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Authors of TADS study reply to letter raising concerns

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Treatment benefit and the risk of suicidality in multicenter, randomized, controlled trials of sertraline in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Selective serotonin reuptake inhibitor use in the treatment of the pediatric non-obsessive-compulsive disorder anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Depressed Adolescents Grown Up

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Did regulators fail over selective serotonin reuptake inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Antidepressants and violence: problems at the interface of medicine and law

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Expanding the black box - depression, antidepressants, and the risk of suicide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Postmarketing surveillance of suicidal adverse events with pediatric use of antidepressants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

The relevance of pharmacokinetic studies in designing efficacy trials in juvenile major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

The Food and Drug Administration's deliberations on antidepressant use in pediatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Why we need observational studies to evaluate the effectiveness of health care

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Suicide risk during antidepressant treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Suicide risk and the SSRIs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Age effects on antidepressant-induced manic conversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Psychotherapy for depression among children and adolescents: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Differences in Brain Glucose Metabolism Between Responders to CBT and Venlafaxine in a 16-Week Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Psychopharmacologic treatment of pediatric major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

A feasibility study of the childhood depression medication algorithm: the Texas Children's Medication Algorithm Project (CMAP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

How fixed are child psychiatrists' views about ECT in the young?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

Fluoxetine 40–60 mg versus Fluoxetine 20 mg in the Treatment of Children and Adolescents with a Less-Than-Complete Response to Nine-Week Treatment with Fluoxetine 10–20 mg: APilot Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670802050538

10.1080/00048670802050538

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference